Nuvalent, Inc. — Director's Dealing 2021

Jul 29, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Nuvalent, Inc. (NUVL)
CIK: 0001861560
Period of Report: 2021-07-28

Reporting Person: Hack Andrew A. F. (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Class A Common Stock (2639014)		Indirect

Footnotes

F1: Each share of the Issuer's Series B Preferred Stock is convertible, at the option of the holder, into 0.1858 shares of the Issuer's Class A Common Stock and will automatically convert immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.

F2: Represents shares of the Issuer's Series B Preferred Stock held by Bain Capital Life Sciences Fund II, L.P. ("BCLS II") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II, the "Bain Capital Life Sciences Entities").

F3: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS II and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. As a result, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.